To date, efforts to establish pluripotent embryonic stem cells from bovine embryos have failed. The lack of reliable pluripotency markers is an important drawback when attempting to derive these cells. This study aimed to identify genes upregulated in the inner cell mass (ICM) of bovine blastocysts, and we selected SOX2 for further characterization. Spatial and temporal localization of the SOX2 protein revealed that its expression starts at the 16-cell stage and then becomes restricted to the ICMs of blastocysts. To study the role of SOX2 during the early development of bovine embryos, we designed siRNA to target SOX2. We began by injecting this siRNA into zygotes; the rate at which blastocysts developed declined compared to noninjected or scramble-injected controls. When only one blastomere of a two-cell embryo was injected with SOX2 siRNA, we observed development rates similar to those of controls. Daughter cells of the injected blastomere were tracked by TRITC fluorescence and found to contribute to the ICM, as select cells also lacked SOX2. Gene expression analysis revealed a decrease in SOX2 and NANOG gene expression in siRNAinjected embryos, but OCT4 expression remained unchanged. We conclude that SOX2 localizes exclusively in the ICM of bovine blastocysts, and its downregulation negatively impacts preimplantation development; however, it is still unclear as to why downregulation of SOX2 in one cell of a two-cell embryo does not affect the composition of the ICM.
INTRODUCTION
Pluripotent embryonic stem cells (ESCs) were isolated three decades ago in the mouse [1, 2] . These cells, extensively used to produce transgenic mice by injection in the blastocyst (BL) [3] , have also proven quite effective as nuclei donors to improve the outcome of somatic cell nuclear transfer [4] . Obtaining ESCs in bovine species would be quite useful for producing transgenic and cloned animals. Several attempts have been made, but nobody has reported deriving bona fide pluripotent ESCs [5] [6] [7] [8] [9] [10] . One obstacle is that the same pluripotency markers established in mice and humans seem ineffective for identifying bovine ESCs.
OCT4, NANOG, and SOX2 are transcription factors expressed in the inner cell mass (ICM) of mouse BLs [11] [12] [13] . These genes are excellent markers for mouse and human ESCs or induced pluripotent cells [14] [15] . In addition, the cell surface pluripotency marker SSEA-1, which recognizes the mouse ICM [16] , has proven effective for characterizing mouse ESCs [2] . Curiously, SSEA-1 does not mark human ESCseven though humans and mice share the expression of SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81 [17] -indicating that differences exist across species. These differences point to the fact that while both mouse and human ESCs can display the pluripotent characteristics of indefinite self-renewal and capacity to differentiate, they differ in their ''pluripotency signature.'' Interestingly, OCT4, NANOG, SSEA4, TRA-1-60, and TRA-1-81 are expressed in both the ICM and the trophectoderm (TE) of bovine BLs [18] [19] [20] . In the human preimplantation embryo, OCT4 is not restricted to the ICM [21] [22] [23] ; however, SOX2 and NANOG are expressed in the ICM only [23, 24] .
Little is known about the expression of SOX2 in the bovine embryo. SOX2 is part of the SOX protein family, which comprises 20 genes. Each of these genes contain a DNAbinding HMG domain and both nuclear import and export signals, and they act as transcription factors [25, 26] . In the mouse, SOX2 mRNA is initially expressed in some cells of the morula and then becomes restricted to the ICMs of BLs; however, maternal protein is detected in oocytes and throughout the preimplantation embryo until the BL stage [13] . SOX2 is required to maintain pluripotency in mouse ESCs [27] and is also one of four factors used to induce pluripotency in differentiated cells [28] . SOX2 is also expressed in adult stem cells of several tissues, including testis stem cells that can reconstitute spermatogenesis in infertile mice [29] . We hypothesized that SOX2 marks pluripotency in bovine embryos and also that it is required for the formation of the ICM in BLs.
In this study, we evaluated the differences in gene expression between ICMs and TEs by comparing the expression of isolated TEs with whole BLs. We also characterized the temporal and spatial expression of the SOX2 protein during bovine embryo development, after which we performed knockdown experiments to assess the requirement for SOX2 in bovine preimplantation development.
MATERIALS AND METHODS
All reagents were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise stated. This project was exempt from internal animal care and use approval, as samples were collected from postmortem animals according to the Institutional Animal Care and Use Committee at Michigan State University.
Bovine oocytes were obtained by aspirating ovaries collected at a commercial slaughterhouse (JBS, Plainwell, MI), as described [30] . We selected cumulus-oocyte complexes according to their quality and placed them into maturation media consisting of medium 199 supplemented with 10% FBS, 3 lg/ml luteinizing hormone (Sioux Biochemical, Sioux Center, IA), 3 lg/ml follicle-stimulating hormone (Sioux Biochemical), 22 lg/ml sodium pyruvate, and 25 lg/ml gentamycin (Life Technologies, Grand Island, NY). After 22 h, oocytes were submitted to either in vitro fertilization or parthenogenetic activation (PA). IVF took place in Tyrode albumin lactate pyruvate (TALP)-based fertilization media [31] supplemented with 20 lg/ml of heparin. After thawing, we added live sperm cells, selected by Percoll gradient, to the well containing the oocytes at a concentration of 1 310 6 sperm cells/ml. Fertilization occurred over a period of 18 h at 38.58C and 5% CO 2 in high humidity. After 18 h, presumptive zygotes were stripped of cumulus after 3 min of vortexing and washed in Hamster Embryo Culture Medium [32] -Hepes (HH) media before being placed into microdrops of KSOM þ AA medium (Millipore, Billerica, MA) under oil and cultured at 38.58C in high humidity. At Day 3 of culture, we assessed the cleavage rates and supplemented the medium with 5% FBS. At Day 7.5, the BL rates (BL/oocyte number) were assessed. For parthenogenetic active PA oocytes, we removed the cumulus cells from matured oocytes by vortexing them for 5 min with 1 mg/ml of hyaluronidase. Oocytes were then washed in HH medium and activated by exposing them for 4 min to 5 mM ionomycin (EMD Biosciences, La Jolla, CA) in HH, followed by incubation in 200 mM 6-dimethylaminopurine in KSOM at 38.58C and 5% CO 2 in high humidity. After 4 h, we washed the oocytes in HH, placed them into KSOM drops, and cultured them in vitro as described above.
Gene Expression of TE and Whole Embryos
Three replicates of in vitro-fertilized BLs were collected and divided into two groups. We obtained a minimum of seven and a maximum of 11 embryo samples per group. One group consisted of intact embryos; the other consisted of the TE separated from the ICM using a sharp splitting blade (Bioniche Animal Health, Belleville, ON). Intact embryos and TEs were placed in extraction buffer from the PicoPure RNA Isolation Kit (Applied Biosystems, Foster City, CA), incubated at 428C for 30 min, flash frozen in liquid nitrogen, and kept at À808C until RNA extraction. RNA isolation was carried out using PicoPure, following the manufacturer's instructions, including a DNase (Qiagen, Hilden, Germany) incubation step. Reverse transcription reaction was performed using Superscript II Reverse Transcriptase kit (Life Technologies) with 250 ng of random primers (Promega, Madison, WI) following the manufacturer's instructions. After quantification with a Nanodrop spectrophotometer (Thermo Scientific, Rochester, NY), we diluted the resulting cDNA to 2 lg/ml. We used the ABI 7000 Detection System to perform duplicate quantitative PCR reactions for each sample, setting them with SYBR Green 23 PCR Master Mix (Applied Biosystems) and 2 ll of cDNA. We used thermal cycle settings of 40 cycles at 958C for 15 sec and at 608C for 60 sec. H2A and GAPDH genes were used for housekeeping to normalize the expression of target genes. Supplemental Table S1 (available online at www.biolreprod.org) describes the primers used.
Immunocytochemistry
All solutions were prepared with PBS. In vitro-fertilized embryos were collected at the zygote, 2-, 4-, 8-, and 16-cell stages, at 16, 30, 40, 52 , and 72 h after insemination, respectively. We collected morulae at Day 5 and BLs at Day 7.5 after insemination. Embryos were fixed using 4% paraformaldehyde for 20 min at room temperature, followed by three washes in PBS with 1 mg/ml polyvinylpyrrolidone, in which they were stored at 48C until further processing. Embryos were permeabilized using 0.5% Triton X-100 solution for 15 min and then placed for 1 h at room temperature in blocking solution containing 0.1% Triton X-100, 1% BSA, and 10% horse serum. Incubation with a primary antibody against SOX2 (1:200; either AB5603 from Millipore or SC17320 from Santa Cruz Biotechnology, Santa Cruz, CA) occurred overnight at 48C in 0.1% Triton X-100 and 1% BSA solution. We then washed embryos three times for 15 min in 0.1% Triton X-100 solution. Incubation with anti-goat secondary antibody (1:400; Jackson ImmunoResearch, West Grove, PA) followed for 1 h at room temperature in the dark. Embryos were then washed three times for 15 min in the dark and mounted on slides with Prolong Gold Antifade Reagent with DAPI (Life Technologies). We visualized embryos using an inverted spinning-disk confocal microscope and obtained stacks of pictures using Metamorph software (Molecular Devices, Sunnyvale, CA).
Semiquantitative Analysis of SOX2 Protein Expression
Using Image J software (U.S. National Institutes of Health, Bethesda, MD; http://imagej.nih.gov/ij), we performed intensity quantification of SOX2 protein by delineating each nucleus. The software calculated average pixel intensity. Data were normalized by an average of two background regions for each projection. Average intensity of each embryo was considered for statistical analysis. Number of images analyzed per stage was three 1 cell, three 2 cell, three 8 cell, three 16 cell, seven morulae, and seven BLs.
Small Interfering RNA Synthesis and Validation
Target sequences for the bovine SOX2 gene (GenBank accession no. NM_001105463) were designed using TargetFinder software from Ambion (no longer available). Oligonucleotides for use with the Ambion Silencer siRNA Construction Kit (Life Technologies) were designed using the siRNA Template Design Tool online software, also from Ambion (discontinued), as described in Supplemental Table S1 . We synthesized three different siRNAs against three different positions of the single-exon-coded SOX2 mRNA. We also synthesized a scrambled (SCR) siRNA that would not target any other bovine gene, as verified by the NCBI BLAST online resource. In order to validate these siRNAs, we collected injected Day 5 morulae and then either performed RNA extraction and subsequent quantitative PCR on them, as described above, or fixed for SOX2 immunocytochemistry.
Microinjection of Zygotes and Two-Cell Embryos
After 18 h of incubation for in vitro fertilization, presumptive zygotes were denuded by vortexing in HH medium. They were washed to remove excessive sperm and cumulus cells and placed into microdrops of HH supplemented with 20% FBS. We performed microinjection as described previously [33] . Briefly, we loaded 40 lM SOX2 siRNA or SCR siRNA with 2 mg/ml TRITC-labeled dextran (TRITC-dextran, MW 70 000) into a 0.8-to 1.0-lm-diameter glass micropipette. We aspirated the zygote cytoplasm until the membrane was broken and then injected a volume of 6 to 8 pl into each zygote. Injected zygotes were placed into KSOM microdrops and cultured as described above. Day 5 morulae were collected for quantitative PCR to validate siRNAs. We assessed the BL rate at Day 7.5.
In order to inject one blastomere of a two-cell embryo, we cultured PAderived embryos in KSOM for 30 h after activation. We performed injections as above; however, we injected a volume of 3 to 4 pl into only one of the cells. Day 5 morulae were collected for immunocytochemistry to verify knockdown of SOX2. We collected Day 7.5 BLs for gene expression analysis and immunocytochemistry as described above as well as for differential cell counting. Cleavage and BL rates were based on total number of cultured twocell embryos that immediately survived the injection.
Differential Cell Counting
We performed differential staining of BLs as described previously [34] , with minor modifications. Briefly, embryos were incubated with 1% Triton X-100 in PBS containing 100 lg/ml propidium iodide for 40 sec. We fixed BLs overnight in absolute ethanol with 25 lg/ml Hoechst 33342 at 48C and analyzed them with an inverted fluorescence microscope (TE-2000; Nikon, Tokyo, Japan). Performing four replicates, we compared 27 noninjected control embryos to 34 SCR-injected and 23 siRNA3-injected embryos.
Statistical Analysis
We analyzed data using SAS 9.3 software (SAS Institute, Cary, NC). Independent variables were the groups (whole BL or TE) and the treatments (control, SCR, or siRNA). Cell number and fluorescence intensity were considered dependent variables, and data were analyzed by analysis of variance (ANOVA) using PROC MIXED, with Tukey adjustment as a post hoc test to compare means. Each replicate consisted of a different oocyte batch and was included in the model as a random variable. Cleavage rates and BL rates were also considered dependent variables and analyzed by ANOVA using PROC GLM, with Tukey adjustment as a post hoc test to compare means. Quantitative PCR data were analyzed using PROC MIXED, as described previously [35] . We present the results in graphs in log 2 distribution; throughout the text, we use the relative fold change to facilitate data interpretation. Number of replicates and significant statistical differences are indicated throughout the text and in figure legends.
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RESULTS
Differences in Gene Expression Between TEs and Whole Embryos
We divided in vitro-derived BLs into two groups for RNA isolation, reverse transcription, and relative PCR quantification. One group consisted of intact BLs. In the other group, we mechanically isolated the TE by splitting with a sharp blade. We expected this design to identify genes that were either exclusively or highly expressed in the ICM of bovine BLs since those would have lower levels of expression or not be present in the TE. This experiment focused on genes known to correlate to pluripotency in mice and humans. Figure 1 summarizes our results. We observed the different expression levels of LIFR, KLF4, and OCT4, which displayed a trend (P 0.10) to be higher in BL samples than in TE samples. Several genes showed significant upregulation (P 0.05) in the ICM: LIN28, 2-fold; FGFR4, 4-fold; NANOG, 11-fold; and SOX2, 7-fold. The genes REX1, RONIN, and GDF3 did not present statistical difference. The NANOG protein was already characterized in the bovine embryo [19, 20] ; thus, we decided to explore the roles of SOX2. Note that we detected all of the tested genes in TE samples, albeit at relatively lower levels.
Temporal and Spatial Localization of SOX2 Protein
In order to establish the dynamics of SOX2 protein expression, we collected preimplantation embryos at all stages of development, from zygote to BL, and fixed them for immunocytochemistry. From the zygote to the eight-cell embryo stage, we observed no noticeable SOX2 protein expression. However, at the 16-cell stage, we detected SOX2 protein in all cells of most embryos, a pattern also observed at the morula stage (Fig. 2) . Curiously, at the BL stage, SOX2-positive cells were restricted to the ICM (Fig. 2) , which would make SOX2 the first specific protein marker of bovine ICM. We used two different antibodies at the BL stage to ensure that the staining was indeed of the SOX2 protein (Fig. 2) , which is mostly nuclear within the cells. We also quantified the fluorescence intensity of SOX2 staining and observed an increase in the 16-cell and morula stage when compared to all other stages (P 0.05; Fig. 3 ). Intensity of SOX2 staining in the BL stage was higher than in the one-, two-, and eight-cell stages (P 0.05; Fig. 3 ).
SOX2 siRNA Injection
We designed three different siRNAs against the bovine SOX2 mRNA sequence. We injected in vitro-fertilized zygotes with these siRNAs and with SCR siRNA. Noninjected zygotes served as a control. At Day 5, we collected morulae for RNA isolation, knowing that these embryos should already express SOX2. Using quantitative PCR, we found that siRNA1 reduced SOX2 mRNA levels by 11%, while siRNA2 and siRNA3 reduced SOX2 levels to about 45% (Fig. 4A) . We decided to combine siRNA2 and siRNA3; together, they produced a 74% knockdown of SOX2 (Fig. 4A ). Embryos injected with siRNA2 and 3 were cultured until the BL stage; however, significantly fewer embryos reached this developmental stage: 7.16% (5/68) compared to 26.23% (22/71) and 30.86% (19/72) of noninjected control and SCR-injected groups, respectively (Fig. 4B) .
This reduction in BL development could have been caused by an impairment of ICM formation or by the blocked development of all cells in the embryo. To address this issue, we decided to inject one blastomere of a two-cell embryo and to trace that cell and its daughter cells with a coinjection of TRITC-dextran (MW 70 000; Fig. 4C ), which cannot escape the cells once delivered intracellularly. However, when using IVF, we had several embryos at different developmental time points, including one-, two-, or four-cell embryos. The latter when injected would die more easily. In order to synchronize the number of two-cell embryos at the time of injection, we opted to produce embryos by parthenogenesis, artificially activating them with ionomycin. For all experiments from now on, we used these parthenogenetic derived embryos, in which we injected only one blastomere at the two-cell stage. We observed that some cells of the embryo (but not all) were stained with TRITC at the eight-cell stage (Fig. 4D) and in some cells of the morulae. Immunocytochemistry did not detect the SOX2 protein in the injected daughter cells. Semiquantification was not used in this validation since differences 
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between cells within the same embryo were very obvious to the naked eye. (Fig. 4E) .
We assessed cleavage beyond the two-cell stage, and observed a trend for lower rates in SCR-injected cells (133/ 211, 63.2%, P ¼ 0.07) and significantly lower rates in siRNAinjected groups (109/183, 58.92%, P ¼ 0.01) than in the noninjected controls (208/289, 73.9%; Fig. 5A ). However, BL formation rates remained unchanged among SCR, siRNA, and control groups: 54.0% (114/211), 45 .9% (84/183), and 46.3% (134/289), respectively (Fig. 5A) . BLs derived from siRNA injections displayed TRITC staining at the ICM and had cells negative for SOX2 protein in the ICM-and even one BL that had no SOX2-positive cells (Fig. 6 )-suggesting that SOX2 might not be required for ICM formation (Fig. 5B) .
Even though blastomeres injected with SOX2 siRNA could contribute to the ICM, we speculated that the number of ICM cells in such embryos could be reduced. We performed differential staining analysis on Day 7.5 BLs and observed no difference in ICM cell number, TE cell number, total cell number, or ICM:TE ratio among all treatment groups (Table 1) .
Quantitative PCR Gene Expression Analysis
Parthenogenetic activated embryos that had one blastomere injected at the two-cell stage were obtained after 7.5 days in culture and submitted to RNA isolation and quantitative RT-PCR. SOX2 levels were significantly (P 0.05) reduced by 43% in the siRNA group compared to noninjected controls, while SOX2 expression in SCR-injected embryos was not statistically different (Fig. 7) . Embryos injected with siRNA showed a significant (P 0.05) 55% reduction in NANOG expression, while SCR-injected embryos were not statistically different when compared to controls (Fig. 7) . We tested expression of OCT4, which was not statistically different among the three groups (Fig. 7) . Our initial data showed the upregulation of FGFR4 in the ICM; however, knockdown of SOX2 did not alter the expression levels of this gene (Fig. 7) . Knockdown of SOX2 did not interfere with CDX2 gene expression levels (Fig. 7) .
DISCUSSION
Establishment of pluripotent ESCs from bovine embryos so far has proven unsuccessful. Interestingly, bovine BLs display a different pattern of pluripotency markers than mouse embryos. Some of the most common markers, such as OCT4 and NANOG, are expressed in both ICM and TE [18] [19] [20] . SOX2, a transcription factor widely used as a pluripotency marker and required for pluripotency maintenance in mice [27] , has not been properly studied in the bovine embryo. In this study, we assessed the difference of gene expression between mechanically isolated TEs and whole BLs; we verified SOX2 protein localization in the BL and tested the hypothesis that SOX2 is required for bovine ICM formation and therefore a potentially important marker for pluripotent cells.
In the search for ICM markers in the bovine BL, we obtained RNA from mechanically isolated TEs and whole BLs. We reasoned that any gene significantly upregulated in the ''whole BL'' group would indicate genes enriched in the ICM. FGFR4 was one of the genes significantly upregulated in samples containing the ICM. In mice, FGFR4 is expressed in both ICM and TE but is restricted to the epiblast and primitive endoderm later in development [36] . This may indicate GOISSIS AND CIBELLI temporal differences between bovine and mouse embryos. We found significantly higher levels of SOX2, NANOG, and LIN28 in samples containing the ICM when compared to the TE. Since NANOG protein localization was already shown in cows [19, 20] and LIN28 fold change was not as pronounced as SOX2, we concentrated our efforts on the latter.
Immunocytochemistry showed that SOX2 expression first appears at the 16-cell stage, which differs from the two-cell stage in the mouse [13] and coincides with bovine embryonic genomic activation, occurring at the 8-to 16-cell stage [37, 38] . SOX2 protein expression at the BL stage is restricted to the ICM, unlike other pluripotency markers, such as OCT4, Values are presented as log 2 (FC) 6 SEM. Asterisks indicate significant statistical difference from control group (*P 0.05; **P 0.01); n ¼ 3, pools of 7 to 10 embryos. B) BL rates 6 SEM from noninjected, SCR-injected, or siRNA-injected zygotes. BL rates were 26.23% (22/71), 30.86% (19/72), and 7.16% 5/68) for the control, SCR, and siRNA groups, respectively Asterisks indicate significant statistical difference from control group (P 0.05); n ¼ 5. C) Representative image of a twocell embryo with one blastomere injected with SOX2 siRNA and TRITC-dextran. D) Representative image of an eight-cell embryo that had one blastomere injected at the two-cell stage with SOX2 siRNA and TRITC-dextran. E) Representative image of SOX2 immunocytochemistry of a morula that had one blastomere injected at the two-cell stage with SOX2 siRNA and dextran-TRITC. Bar ¼ 40 lm.
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NANOG, SSEA-4, and TRA-1-60 [19, 20] . Interestingly, we also detected SOX2 mRNA in the TE samples of our preliminary gene expression experiment. While isolating the ICM from the TE, we were careful to use only TE that was clearly cut without ICM. The ICM isolates contained polar TE, which we believe did not influence the interpretation of our data. In our opinion, the TE samples we isolated would provide good comparison to the ICM samples in order to find genes that were upregulated but not downregulated in the ICM.
We could not detect SOX2 protein expression in the TE using two different antibodies. Even so, we cannot rule out the possibility that SOX2 is expressed at the TE, albeit at sufficiently low levels that they fall below the sensitivity of our technique. Another possibility would be that in the TE GOISSIS AND CIBELLI cells, SOX2 mRNA is postranscriptionally regulated by microRNAs, such as miR145 [39] . Our data indicate that SOX2 appears as the first transcription factor described in the bovine embryo that could be used as a specific marker for bovine ICM. During the preparation of this article, Khan and colleagues [40] confirmed our findings that SOX2 protein is restricted to the ICM in D7 bovine embryos, even though SOX2 mRNA is present in the TE. The semiquantitative analysis of SOX2 protein staining revealed a similar pattern to SOX2 mRNA expression [40] .
In order to test the hypothesis that SOX2 is required for ICM formation in bovine BLs, we designed and injected siRNA into Due to the use of PA embryos in the final experiments, it is possible that IVF embryos would have a different outcome, especially regarding TE cell numbers and gene expression [42] . However, another study showed that IVF and PA embryos have small numbers of differentially expressed genes, and SOX2 was not among those genes [43] . Considering that the sex of the embryo does not influence the expression of SOX2, as shown by global gene expression analysis of female and male IVF embryos [44] , we did not sex the embryos.
Despite the trend in reduction of SCR-injected embryos cleavage rates and reduced rates of siRNA-injected embryos, embryos that had only one cell injected with SCR or siRNA reached the BL stage at the same rate as noninjected controls. These lower cleavage rates are probably due to technical issues, as injections are not as innocuous as reported in mouse studies. In the bovine species, prior to injection, aspiration of the cytoplasm [33] is required, and this in turn could cause cell lysis leading to embryo death at early stages.
Unexpectedly, injected cells contributed to the ICM, as we confirmed by tracking the cells with coinjection of TRITCdextran and by the lack of SOX2-positive cells within the ICM itself. More interestingly, we observed one embryo that completely lacked SOX2 protein, providing more evidence that ICM formation seems not to require SOX2, as all cells might have been derived from the injected blastomere. Nor did injection of SOX2 siRNA influence cell number and allocation. The role of SOX2 in the mouse is still subject to debate. Homozygous deletion of SOX2 yielded normal BLs [13] that failed to survive right after implantation. Knockdown of SOX2 arrested embryos at the morula stage, reducing expression of TE-related proteins at that stage [45] . However, Pan and Schultz [41] point out that maternal SOX2 protein would still be present in these aforementioned studies.
The decline of the bovine BL rate after SOX2 siRNA injection in zygotes could have occurred because of a failure to activate the embryonic genome, similar to previous observations in which a dominant-negative SOX2 in mice was expressed [41] or, perhaps, because of a failure to regulate trophoblast genes at the morula stage [45] . Based on our data, the second scenario seems unlikely due to the contribution of daughter cells of an injected blastomere to the TE. Considering the first scenario, we believe the siRNA-injected cells were able to overcome developmental arrest due to the presence of other cells undergoing embryonic genome activation (EGA). Others have shown that phosphatidylinositol 3-kinase (PI3K) signaling through the AKT pathway is required for mouse EGA [46] . PI3K-AKT signaling can be activated by different embryotropins that act, in relation to the embryo itself, in an autocrine manner [47] . Based on this information, we speculate that noninjected cells secrete specific embryotropins that act through PI3K-AKT signaling in injected cells, allowing them to undergo proper EGA. Further studies will be required to discover the mechanisms of the developmental arrest after SOX2 knockdown in zygotes.
SOX2 is part of the so-called pluripotency network, in which it plays a central role, along with OCT4 and NANOG [48] . These genes self-regulate and regulate each other's expression and often bind to the same target genes, maintaining the pluripotency program [49] [50] [51] [52] . Knockdown of SOX2 led to a reduction in NANOG expression in bovine BLs, probably due to SOX2 regulation of NANOG, as mentioned above. NANOGnull mouse embryos can form an ICM. However, these embryos are not viable and cannot be used for ESC derivation, as cells cannot retain pluripotency and differentiate into endoderm-like cells [53] or trophoblast cells or undergo cell death [54] . Curiously, OCT4 expression was not reduced, as would be expected considering its interactions with SOX2. However, some have suggested that during bovine development, OCT4 and SOX2 do not interact, as occurs in mice or humans [55] , which could explain the observed result.
It will require further studies to determine the long-term effect of embryos having a SOX2-deficient ICM. In vitro studies of these embryos would benefit from the derivation of GOISSIS AND CIBELLI bona fide bovine ESCs. Unfortunately, such cells have not been reported yet. Transfer of these embryos into recipient cows would offer limited information due to the short knockdown effect of SOX2 siRNA injections. Considering the role of SOX2 in the adult animal, conditional knockdown using siRNAs coded in the genome could provide the best option.
Our study revealed that the SOX2 protein is limited to the ICM of bovine BLs. Knockdown of SOX2 following the zygote stage had a negative impact on development to BL; however, injection of SOX2 siRNA into a single blastomere of a two-cell embryo did not. Moreover, these injected cells were able to contribute to the ICM, even though NANOG expression was also reduced in BLs. Based on the data presented, we conclude that SOX2 is a protein marker for the ICM, although it may not be required for ICM formation in bovine embryos.
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